| pubmed-article:7260872 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7260872 | lifeskim:mentions | umls-concept:C1261473 | lld:lifeskim |
| pubmed-article:7260872 | lifeskim:mentions | umls-concept:C0001675 | lld:lifeskim |
| pubmed-article:7260872 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:7260872 | lifeskim:mentions | umls-concept:C0010934 | lld:lifeskim |
| pubmed-article:7260872 | lifeskim:mentions | umls-concept:C0036637 | lld:lifeskim |
| pubmed-article:7260872 | lifeskim:mentions | umls-concept:C0220825 | lld:lifeskim |
| pubmed-article:7260872 | lifeskim:mentions | umls-concept:C0205390 | lld:lifeskim |
| pubmed-article:7260872 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:7260872 | pubmed:issue | 12 | lld:pubmed |
| pubmed-article:7260872 | pubmed:dateCreated | 1981-10-29 | lld:pubmed |
| pubmed-article:7260872 | pubmed:abstractText | Twenty-nine patients with metastatic sarcoma were treated with a combination of methyl CCNU and actinomycin D. Patients with adequate bone marrow reserve received methyl CCNU 100 mg/m2 orally on day 1 and actinomycin D 0.3 mg/m2/day intravenously for five days. Both drugs were repeated every four weeks. Patients with inadequate bone marrow reserve received methyl CCNU 75 mg/m2 and actinomycin D 0.2 mg/m2/day for five days. All patients had received prior chemotherapy and had progressive disease at the start of the study. There was one complete response in a patient with peritoneal mesothelioma which lasted 18 months and the patient is still alive at 38+ months. Ten patients had stable disease including three patients who had responses between 25% to 50%. No responses were seen in 18 patients. The median time to progression for patients with stable disease was five months and for those with progressive disease was two months (P = 0.001). The median survival for patients with stable disease was 20 months compared with three months for patients with progressive disease (P = 0.001). The combination was generally very well tolerated and myelosuppression was insignificant. However, with the dosages and schedule used in this study, the combination of methyl CCNU and actinomycin D does not appear to have significant activity in advanced soft tissue sarcomas. Further studies with this combination are indicated in patients with mesothelioma. | lld:pubmed |
| pubmed-article:7260872 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7260872 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7260872 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7260872 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:7260872 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7260872 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7260872 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7260872 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7260872 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:7260872 | pubmed:issn | 0008-543X | lld:pubmed |
| pubmed-article:7260872 | pubmed:author | pubmed-author:BodeyG PGP | lld:pubmed |
| pubmed-article:7260872 | pubmed:author | pubmed-author:SinkovicsJ... | lld:pubmed |
| pubmed-article:7260872 | pubmed:author | pubmed-author:BurgessM AMA | lld:pubmed |
| pubmed-article:7260872 | pubmed:author | pubmed-author:MurphyW KWK | lld:pubmed |
| pubmed-article:7260872 | pubmed:author | pubmed-author:BenjaminR SRS | lld:pubmed |
| pubmed-article:7260872 | pubmed:author | pubmed-author:YapB SBS | lld:pubmed |
| pubmed-article:7260872 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7260872 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:7260872 | pubmed:volume | 47 | lld:pubmed |
| pubmed-article:7260872 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7260872 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7260872 | pubmed:pagination | 2807-9 | lld:pubmed |
| pubmed-article:7260872 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:7260872 | pubmed:meshHeading | pubmed-meshheading:7260872-... | lld:pubmed |
| pubmed-article:7260872 | pubmed:meshHeading | pubmed-meshheading:7260872-... | lld:pubmed |
| pubmed-article:7260872 | pubmed:meshHeading | pubmed-meshheading:7260872-... | lld:pubmed |
| pubmed-article:7260872 | pubmed:meshHeading | pubmed-meshheading:7260872-... | lld:pubmed |
| pubmed-article:7260872 | pubmed:meshHeading | pubmed-meshheading:7260872-... | lld:pubmed |
| pubmed-article:7260872 | pubmed:meshHeading | pubmed-meshheading:7260872-... | lld:pubmed |
| pubmed-article:7260872 | pubmed:meshHeading | pubmed-meshheading:7260872-... | lld:pubmed |
| pubmed-article:7260872 | pubmed:meshHeading | pubmed-meshheading:7260872-... | lld:pubmed |
| pubmed-article:7260872 | pubmed:meshHeading | pubmed-meshheading:7260872-... | lld:pubmed |
| pubmed-article:7260872 | pubmed:meshHeading | pubmed-meshheading:7260872-... | lld:pubmed |
| pubmed-article:7260872 | pubmed:meshHeading | pubmed-meshheading:7260872-... | lld:pubmed |
| pubmed-article:7260872 | pubmed:meshHeading | pubmed-meshheading:7260872-... | lld:pubmed |
| pubmed-article:7260872 | pubmed:meshHeading | pubmed-meshheading:7260872-... | lld:pubmed |
| pubmed-article:7260872 | pubmed:meshHeading | pubmed-meshheading:7260872-... | lld:pubmed |
| pubmed-article:7260872 | pubmed:meshHeading | pubmed-meshheading:7260872-... | lld:pubmed |
| pubmed-article:7260872 | pubmed:year | 1981 | lld:pubmed |
| pubmed-article:7260872 | pubmed:articleTitle | A phase II evaluation of methyl CCNU and actinomycin D in the treatment of advanced sarcomas in adults. | lld:pubmed |
| pubmed-article:7260872 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7260872 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7260872 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7260872 | lld:pubmed |
